nesiritide trial summary

Acute heart failure

All type of patients: 10 trials - NSGET (efficacy trial) - VMAC (24h) - PROACTION - BNP-CARDS - FUSION 2 - ASCEND-HF - VMAC (intravenous neseritide) - NSGET (comparative trial) - FUSION 1 - PRECEDENT

nesiritide vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs dobutamine

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs nitroglycerin

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	1.56 [0.76 3.19]	p=1.00	0	498	1	VMAC (24h),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	1.11 [1.00 1.23]	p=1.00	0	7007	1	ASCEND-HF,
30-day death	0.90 [0.70 1.15]	p=1.00	0	7007	1	ASCEND-HF,
Death from any cause or hospitalization for heart failure	0.93 [0.80 1.10]	p=1.00	0	7007	1	ASCEND-HF,
hospitalisation for heart failure	0.98 [0.81 1.20]	p=1.00	0	7007	1	ASCEND-HF,
All cause death	0.93 [0.73 1.18]	p=1.00	0	7371	3	NSGET (efficacy trial),PROACTION,ASCEND-HF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs standard care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Heart failure

Acute decompensated heart failure: 9 trials - NSGET (efficacy trial) - VMAC (24h) - PROACTION - BNP-CARDS - ASCEND-HF - VMAC (intravenous neseritide) - NSGET (comparative trial) - FUSION 1 - PRECEDENT

nesiritide vs control

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs dobutamine

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs nitroglycerin

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	1.56 [0.76 3.19]	p=1.00	0	498	1	VMAC (24h),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	1.11 [1.00 1.23]	p=1.00	0	7007	1	ASCEND-HF,
30-day death	0.90 [0.70 1.15]	p=1.00	0	7007	1	ASCEND-HF,
Death from any cause or hospitalization for heart failure	0.93 [0.80 1.10]	p=1.00	0	7007	1	ASCEND-HF,
hospitalisation for heart failure	0.98 [0.81 1.20]	p=1.00	0	7007	1	ASCEND-HF,
All cause death	0.93 [0.73 1.18]	p=1.00	0	7371	3	NSGET (efficacy trial),PROACTION,ASCEND-HF,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs standard care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

See more clinical conditions

All type of patient: 2 trials - FUSION 2 - FUSION 1

nesiritide vs placebo

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

nesiritide vs standard care

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Amelioration of Dyspnea at 6 h	no data
amelioration of Dyspnea at 24 h	no data
30-day death	no data
Death from any cause or hospitalization for heart failure	no data
hospitalisation for heart failure	no data
All cause death	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Restenosis after PCI

All type of patients: 3 trials - PREVENT - INHIBIT - START

P-32 vs placebo

No demonstrated result

suggested MACE by 32% (not demonstrated)

suggested target-vessel revascularization by 36% (not demonstrated)

suggested target lesion revascularisation by 49% (not demonstrated)

suggested angiographic restenosis by 79% (not demonstrated)

Endpoint	TE [95% CI]	p val	n	k	trials
myocardial infarction (fatal and non fatal)	0.84 [0.34 2.05]	p=1.00	876	3	PREVENT,INHIBIT,START,
MACE	0.68 [0.50 0.93]	p=0.04	876	3	PREVENT,INHIBIT,START,
target-vessel revascularization	0.64 [0.46 0.88]	p=0.04	876	3	PREVENT,INHIBIT,START,
target lesion revascularisation	0.51 [0.32 0.80]	p=0.04	544	2	PREVENT,START,
angiographic restenosis	0.21 [0.06 0.69]	p=0.04	96	1	PREVENT,
All cause death	1.23 [0.43 3.48]	p=1.00	876	3	PREVENT,INHIBIT,START,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Nesiritide atrial natriuretic peptide

Acute heart failure

Heart failure

Restenosis after PCI